Key facts
- It has raised $13.0M; the latest was Early Stage VC ($10.0M) in Dec 2024.
- Notable investors include Financiadora de Estudos e Projetos, Adeste AS, Biominas Brasil, Ecoa Capital, Fundo Pitanga — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Nintx
- ·The full record, as it builds
Funding rounds
No funding rounds for Nintx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nintx
Developer of drugs from medicinal plants designed to translate complex biological interactions into therapies. The company offers plant-based natural products with the potential to serve as a platform to modulate human biological targets and the microbiome concomitantly, enabling patients to get affordable therapies for multifactorial diseases.
- Sector
- Healthcare
- HQ
- Sao Paulo, Brazil
- Founded
- 2021
- Employees
- 9
- Website
- nintx.com.br/
- Ownership
- Privately Held (backing)
Nintx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nintx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nintx in its N-PORT filings yet. We sweep new filings monthly.